A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

NCT02167256 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: AZD0530 100mg daily
DRUG: AZD0530 125mg daily
DRUG: Placebo

Sponsor

Yale University

Collaborators

[object Object]